ArticleJournal of neural transmission (Vienna, Austria : 1996)2025
Insights into insulin signalling and oxidative stress in the Tg2576 mouse model of familial Alzheimer's disease: effects of chronic oral galactose administration.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, metabolic dysregulation, brain insulin resistance, and oxidative stress. Familial AD (fAD) models, like the Tg2576 mice, offer insights into early-onset AD; however, their relevance to sporadic AD remains limited. This study investigated brain insulin signalling and oxidative stress in Tg2576 mice at presymptomatic (7-month) and mild AD (12-month) stages, focusing on the hippocampus and hypothalamus. Additionally, the effects of chronic oral galactose-a proposed insulin-independent energy source-were examined. Oxidative stress parameters remained unchanged across disease progression, aging, and galactose treatment, suggesting that redox processes are not significantly impaired at early stages. Insulin signalling exhibited region- and age-dependent variations, with notable changes in the hypothalamus of 7-month-old transgenic mice. Galactose treatment reduced AMPK activation in both brain regions, potentially reflecting improved energy supply via its conversion to glucose through the Leloir pathway. By 12 months of age, hippocampal alterations became more pronounced, including reduced p70S6K activity in transgenic mice, consistent with impaired mTOR signalling in AD. Galactose modulated p70S6K activity differently based on age and genotype: it increased activity in younger wild-type mice, stimulating anabolic processes, while decreasing activity in older wild-type animals. GLUT4 expression also showed nuanced responses to aging, genotype, and galactose treatment. These results highlight the heterogeneity of AD pathophysiology and the limitations of using a single model to represent the disease. The study underscores the need for broad preclinical research to address biological variability and refine therapeutic approaches for both familial and sporadic AD.
Indexed as
Identifiers
40522496What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.